Clinical Trials Logo

Clinical Trial Summary

The purpose of this study was to assess the safety of Boostrix administered on or after the first day of the 27th week of pregnancy by conducting a post-marketing study that provided safety information to the public and healthcare providers. This was one of the largest cohorts of pregnant women vaccinated with Boostrix in the U.S. Through partnership between Kaiser Permanente Southern California (KPSC) and the sponsor, GlaxoSmithKline (GSK), information about the safety of maternal vaccination with Boostrix and maternal and infant adverse events (AEs) in a community setting was gained.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03463577
Study type Observational
Source GlaxoSmithKline
Contact
Status Completed
Phase
Start date April 13, 2018
Completion date August 4, 2020

See also
  Status Clinical Trial Phase
Completed NCT03035370 - Viaskin Pertussis Vaccine Trial Phase 1
Completed NCT02453048 - Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine Phase 1
Completed NCT01444781 - Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants Phase 3
Active, not recruiting NCT05091619 - A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed Phase 3
Completed NCT02587520 - Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects Phase 1/Phase 2
Completed NCT01983540 - Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination Phase 3
Completed NCT01545115 - Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal N/A
Recruiting NCT04238975 - A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults Phase 2
Completed NCT01439165 - Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Phase 4
Recruiting NCT03751514 - Bordetella Pertussis Colonisation Challenge Study N/A
Active, not recruiting NCT01279668 - Montelukast for Persistent Cough in Young People and Adults Phase 4
Completed NCT00337428 - Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) Phase 3
Completed NCT00662870 - Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine Phase 3
Completed NCT01529645 - Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years Phase 1
Recruiting NCT04036526 - A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine Phase 1/Phase 2
Active, not recruiting NCT02813486 - Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine Phase 1/Phase 2
Completed NCT01629589 - Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Phase 4
Completed NCT03942406 - Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults Phase 2
Completed NCT03137927 - A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine Phase 1
Completed NCT02301702 - Maternal Tdap Immunization in Guatemala Phase 2